Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
clinical trials
3
×
life sciences
national blog main
national top stories
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
cancer
cell therapy
detroit blog main
detroit top stories
diagnostics
immunotherapy
indiana blog main
indiana top stories
medicare
merck
national
new york blog main
new york top stories
nivolumab
novartis
pembrolizumab keytruda
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
abeona therapeutics
What
bio
3
×
drug
3
×
new
3
×
roundup
advantages
analysis
approval
bar
biogen’s
biopharmaceutical
biotech
bring
brings
companies
company
convo
develop
diseases
earlier
employing
expect
failures
gamble
genetic
goldfinch
ipo
kidney
later
lead
littered
market
medco’s
medicines
million
mover
nash
news
patients
payers
physicians
Language
unset
Current search:
bio
×
new
×
" clinical trials "
×
drug
×
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More